HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL - Wikidata - awgldk - TriplyDB

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

http://www.wikidata.org/entity/Q35553330

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Systemic VHL gene functions and the VHL disease Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma KATs in cancer: functions and therapies Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups.Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.Inhibiting DNA Methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation.DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response Targeting Histone Deacetylases in Diseases: Where Are We?Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy Use of class I histone deacetylase inhibitor romidepsin in combination regimens Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.Decitabine in the treatment of acute myeloid leukemia in elderly patients.A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.Role of p53 family members p73 and p63 in human hematological malignancies.HDAC inhibitor-based therapies: can we interpret the code?Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.Transcriptional Selectivity of Epigenetic Therapy in Cancer.Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Factors affecting the persistence of drug-induced reprogramming of the cancer methylome.Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Method to Assess Interactivity of Drugs with Nonparallel Concentration-Effect Relationships.The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.DNA Hypomethylating Drugs in Cancer Therapy.SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.

P2860

Q24597424-F67B774C-7D20-44E1-A1FE-7EAAB5F9080F Q24605882-58A713BD-5F23-480D-932A-707D90E275E8 Q26744080-04D71646-1085-4B70-8A96-CA7BF8CA653A Q26796449-7F9F0F90-FDFB-4D8C-BD3C-E240442BA450 Q26851166-81316F94-6BD3-47EE-A7B1-F2B7B4F1A92A Q26859355-09F97BFE-05F3-4EE3-B8C2-80DC940A0B53 Q27346432-AE5C46B1-B54F-4745-95AA-4EFE8C176068 Q28263221-C5D9377D-5A69-4E79-97D5-E19A4400549D Q33901284-6B00B129-5B58-4910-B4ED-1CC3E780B2C2 Q33913937-1DA79E35-9E41-4C3C-B76B-A8C22F7981C9 Q34345218-82148356-954A-40F9-A43C-4B0977FBB2B3 Q34551679-588E4D21-6B61-4106-9F3F-8DF37D321106 Q35561291-FF377B37-CA2F-4C26-B889-B88C7ED390BC Q35741605-B89A6460-296A-40D0-9434-B8D5CBBFE6C4 Q35821728-5095314F-EE23-4BAE-A118-5809F397995F Q36015007-DF28CAC2-6301-4D5A-9E38-72C6CDB51EF0 Q36172596-2E21D165-DA53-4527-B8B7-2DF98A5E7584 Q36882942-A562D59C-C7AB-440F-BD10-45A46030E94C Q37107439-CC5CE05B-AF50-41DF-B6C9-25AF25648084 Q37117964-ADD493F7-D61C-4126-9519-6232EAC99F54 Q37192391-7A1EEA26-06BC-4021-9659-7BF78588B5F9 Q37568244-27C40FB0-008E-401E-8522-389777AB5EF4 Q37589239-DD054B72-691D-4462-B754-6959A594FC48 Q38002122-3790774D-365D-4B6B-8AEB-3B503A5A09B2 Q38058971-B7CD1F64-A17E-49A7-BB4C-36636C313A2B Q38542620-2CC685A5-650F-44A1-9C7D-44300CAF3B6D Q38725415-C196A07C-2709-454F-B319-E387237A5A0E Q38729313-2CEF0B9A-8D76-47C8-8DE6-FFAEC31F2DA9 Q38735639-A1012E48-0AA6-4C87-BA1B-FDD6956680CC Q38765451-2286EDB4-DBDF-40C2-B483-D1F985ECDBA8 Q38777889-CE5BB818-16F3-4610-8737-B9A697A022E7 Q38790957-B237A63F-6CF0-4572-B995-FC976284D78C Q38819975-A8A5C57F-4E2D-4CCA-BA3B-2551C1F839AE Q38866872-ED392BB0-FFB4-4AB3-89B1-C802801D232D Q38888975-C512127E-0105-4E0D-ADDB-968D54DED5E0 Q38906418-CCA82CFE-0682-4A49-B83A-DF110BE21875 Q38973962-D368DE2C-B0F4-4337-A9EF-31E78D7BD094 Q38979940-0C96E4DD-840E-4BA4-8C23-8C35C4C20173 Q39011822-AD7EE4BA-7AD5-49E9-A820-03D23429D2F5 Q39091822-BFDE9F3A-C153-4805-912F-F736A75E2EF8

P2860

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

http://www.wikidata.org/entity/Q35553330

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL

@ast

HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL

@en

type

label

HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL

@ast

HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL

@en

prefLabel

HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL

@ast

HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL

@en

P1433

Q35553330-90244899-0CAB-44BB-8763-43CA879F3A25

P1476

Q35553330-A2D98B2F-80A8-488E-8221-4E90F7B4C41D

P2093

Q35553330-0EBC42B6-946D-4475-9C24-271B61E3853E

Q35553330-1C2614FD-A86D-4543-BE80-DC47A80A4B55

Q35553330-36489B2E-5C14-40D1-8A18-77393C0E11E9

Q35553330-4B428DB8-6294-4177-9D4D-9FC080AB415D

Q35553330-91A80DA2-F9C4-403C-BDCD-4DB74296C196

Q35553330-9611F65C-D1C0-4A33-B9AA-26FC70F98F60

Q35553330-96D2AA48-0343-49E5-99C7-9C81B0538BA6

Q35553330-B663ED8F-1C99-4704-8B19-B98B016412D8

Q35553330-BE64ED13-344D-40A8-A208-001819F8F350

Q35553330-C665D764-FF2C-48D5-AC33-24EB0366816F

P2860

Q35553330-03C9CC4A-B19F-4D73-BAD9-9FC2DDD64203

Q35553330-121F8D98-37B4-400C-BCE4-CFFFB2CF9748

Q35553330-17566E6E-26AC-4EC0-A183-3EA64E190D17

Q35553330-17D1CAAF-B3AC-45F2-B8BA-2ABFAC3CF29E

Q35553330-23526903-BC84-45D9-A3DE-22A13CD4D20F

Q35553330-377F8024-3834-45E3-90E0-66594CAB3895

Q35553330-47ABF4BA-3875-4605-883D-7CA5417628C9

Q35553330-4C50665D-353D-43E4-97BE-C6C066D7EC33

Q35553330-5A3866EE-D6F5-4A09-A233-F0158E38498C

Q35553330-5C1987BE-9911-428D-9F1F-EEB9D5ED3348

P304

Q35553330-29E93E6E-252F-4294-98B2-710C035219AA

P31

Q35553330-87688740-3DB8-475C-8BB6-1213235BD1C5

P356

Q35553330-A315CFD9-7B4F-4B32-82AE-F7BAAC3BB71E

P407

Q35553330-A0F6B10F-4127-4D62-8D6E-DC94A0A46E5C

P433

Q35553330-E9B704D8-0BC7-43B6-8C7E-E8EDDB5587AB

P478

Q35553330-08F3F773-4B4B-4255-9193-F1347894E763

P577

Q35553330-E76AF562-874E-4AD8-954D-7CB119BED586

P5875

Q35553330-2D59C158-DF0F-48CC-830C-14BED0AB253D

P698

Q35553330-322E0720-4ABA-45BC-B2A8-DA276E183ABA

P932

Q35553330-3A461D7E-FECF-4013-90E8-BA169EED646C

P356

BLOOD-2011-02-336891

P1433

P1476

HDAC inhibitors and decitabine ...... ic profiles in models of DLBCL

@en

P2093

Alexis M Temkin

http://www.w3.org/2001/XMLSchema#string

Benjamin Tycko

http://www.w3.org/2001/XMLSchema#string

Enrica Marchi

http://www.w3.org/2001/XMLSchema#string

Govind Bhagat

http://www.w3.org/2001/XMLSchema#string

Jennifer Amengual

http://www.w3.org/2001/XMLSchema#string

Luigi Scotto

http://www.w3.org/2001/XMLSchema#string

Matko Kalac

http://www.w3.org/2001/XMLSchema#string

Netha Ulahannan

http://www.w3.org/2001/XMLSchema#string

Owen A O'Connor

http://www.w3.org/2001/XMLSchema#string

Samir Parekh

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

DNA methylation patterns and epigenetic memory

Regulation of X-chromosome inactivation in development in mice and humans

The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription

Methylation-induced repression--belts, braces, and chromatin

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.

P304

5506-5516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-336891

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51504938

http://www.w3.org/2001/XMLSchema#string

P698

21772049

http://www.w3.org/2001/XMLSchema#string

P932

3217353

http://www.w3.org/2001/XMLSchema#string